Jespers
Laurent S. Jespers, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20100056439 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 03-04-2010 |
20100247515 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis. | 09-30-2010 |
20120100141 | DRUG FUSIONS AND CONJUGATES - The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. | 04-26-2012 |
20140193407 | DRUG FUSIONS AND CONJUGATES - The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. | 07-10-2014 |
Laurent S. Jespers, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090005257 | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire - The invention relates to polypeptides that unfold reversibly (e.g., unfolds when heated and refolds when cooled), to repertoires containing polypeptides that unfold reversibly and to libraries that contain polypeptides that unfold reversibly or nucleic acids that encode polypeptides that unfold reversibly. The invention further relates to processes for producing a library enriched in polypeptides that unfold reversibly or nucleic acids encoding polypeptides that unfold reversibly, processes for selecting and/or isolating polypeptides that unfold reversibly, and to methods for producing a polypeptide that unfolds reversibly. | 01-01-2009 |
20090214534 | Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY - Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent. | 08-27-2009 |
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
Laurent Stephane Jespers, Tervuren BE
Patent application number | Description | Published |
---|---|---|
20100240584 | Nematode-extracted serine protease inhibitors and anticoagulant proteins - Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA, expression systems. | 09-23-2010 |